Analytical Data
-
Gene name
GFPT1
- Application
-
Alternative Names
GFAT; GFA; •D-fructose-6-phosphate amidotransferase 1; Hexosephosphate aminotransferase 1; Glutamine-fructose-6-phosphate aminotransferase isomerizing 1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q06210
-
Expression Region
Cys2~Gly287
-
Molecular Weight
38kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GFPT1 (Glutamine-Fructose-6-Phosphate Transaminase 1) is an important enzyme in the hexosamine biosynthetic pathway, which plays a crucial role in cellular metabolism and signaling. It catalyzes the conversion of fructose-6-phosphate and glutamine to glucosamine-6-phosphate, a precursor for various glycosylation processes. Aberrant GFPT1 activity has been linked to several metabolic disorders, including obesity, diabetes, and cancer. Research has highlighted its potential as a biomarker for these conditions, as well as its involvement in the modulation of insulin signaling and inflammation. In addition, GFPT1 has garnered attention for its role in the development of complications related to diabetes, such as neuropathy and retinopathy, by influencing the production of advanced glycation end-products (AGEs). Understanding the molecular mechanisms underlying GFPT1's function and regulation is essential for the development of targeted therapies aimed at metabolic diseases. Moreover, the production of recombinant GFPT1 protein has become a focal point for studying its biochemical properties and interactions within the cell, providing insights into its therapeutic potential and paving the way for novel interventions in metabolic dysfunction.
